Science
Precision medicine is the focus of our research. By analysing information about an individual’s characteristics and characterising their immune response, we strive to provide a more personalised approach to the diagnosis and treatment of allergic disease. At Stallergenes Greer, we aim to identify clinical and serological biomarkers that allow us to predict and monitor the efficacy of our allergen immunotherapy (AIT) treatments. As an example, our research supports the interest in IgG2 (immunoglobulin G2, antibodies produced by the immune system during AIT treatment) as an emerging biomarker related to high responders to AIT.”
JAIME SANCHEZ LOPEZ
Investing in data generation
To support the effectiveness of our AIT portfolio, Stallergenes Greer continues to invest in clinical and real-world data generation.
Two randomised clinical studies are underway. YOBI (Young Patients and Birch Allergy) to assess the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma. More than 550 patients across 12 countries were successfully recruited for the study. And in Russia, the Staloral® Mugwort study to evaluate the impact of Staloral® versus placebo on the Average Adjusted Symptom Score for the treatment of patients with mugwort pollen-induced seasonal rhinitis with or without allergic conjunctivitis and/or asthma.
The EfficAPSI real-world study, which includes 430,000 patients in France, to evaluate the therapeutic benefits of sublingual liquid AIT treatment on the onset and worsening of asthma in patients with allergic rhinitis with or without asthma has been finalised and study results will be published in 2024. In Germany, PASS, a post authorisation observational study on the safety of Orylmyte®, the Group’s AIT tablet for house dust mite allergy, is ongoing. Results are expected by the end of 2024.
Leveraging open innovation
In 2023, we continued to foster research collaborations to identify candidate biomarkers of AIT efficacy with the support of world-class organisations including Imperial College London (U.K.), the Swiss Institute of Allergy and Asthma Research (Davos, Switzerland) and Monash University and Alfred Hospital (Melbourne, Australia).
These collaborations will deepen knowledge of the physiopathology of allergic diseases and immune responses (onset of action, memory responses) triggered by AIT which could have implications on the routine practice of allergology.
Stallergenes Greer has also started to explore new therapeutic approaches based on bitherapies combining biologics and AIT solutions with the aim of improving clinical benefits in individuals with allergic asthma.
CORPORATE RESPONSIBILITY FACTS
REAL-WORLD DATA TO INCLUDE THE PATIENT’S PERSPECTIVE IN AIT IMPACT EVALUATION
Real-world data helps gain a better understanding of AIT treatment in real life while enhancing medical knowledge. The Group’s PRACTIS observational prospective study has been finalised with the evaluation of the Patient Benefit index in over 700 patients. This real-world study was designed to show how SLIT met patient expectations when treated for allergic asthma, or allergic conjunctivitis regardless their age and the causal allergen.
Safety, efficacy and effectiveness data on Stallergenes Greer’s AIT products have been collected across the Asia Pacific region, Canada, Europe, the Middle East, the U.S., Russia, and Switzerland.
More than
10,5001
patients included in the Group’s double-blind placebo-controlled studies over 30 years
More than
130,0001
patients treated with the Group’s AIT products in real-world studies over 30 years
I had already been stung by a wasp and didn’t experience any symptoms. The second time, I was gasping, dizzy and my chest was tight. Thankfully, I made it to emergency care in time and was subsequently diagnosed with wasp venom allergy.”